SCHEMBL10195598

SCHEMBL10195598

CC(=O)Nc1ccc(-c2ccc(C)cc2)cn1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 1/20 0.57
ADORA3 P0DMS8 3/20 0.56
RAB9A P51151 3/20 0.56
MAPT P10636 1/20 0.56
WNT3A P56704 1/20 0.53
CYP1A2 P05177 1/20 0.51
GAA P10253 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
PARP1 P09874 1/20 0.49
DHODH Q02127 1/20 0.49
TDO2 P48775 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
TDP1 Q9NUW8 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30338494 0.86 PTK2 (0.57) PTK2ADORA3WNT3ACYP1A2GAA
SCHEMBL423961 0.85 RAB9A (0.75) PTK2RAB9AMAPTCYP1A2GAA
SCHEMBL28118455 0.83 PTK2 (0.54) PTK2CYP1A2GAAKMT2APARP1
SCHEMBL11962288 0.83 ABL1 (0.52) PTK2ADORA3RAB9AMAPTWNT3A
SCHEMBL17316881 0.83 PIK3CG (0.53) PTK2ADORA3RAB9AMAPTCYP1A2
SCHEMBL15317751 0.82 EPHB4 (0.61) PTK2RAB9AMAPTCYP1A2GAA
SCHEMBL17809713 0.82 DEGS1 (0.54) PTK2WNT3ACYP1A2GAAMEN1
SCHEMBL17317003 0.81 TDO2 (0.58) PTK2ADORA3RAB9ACYP1A2GAA
SCHEMBL22975368 0.81 PTK2 (0.56) PTK2WNT3ACYP1A2GAAKMT2A
SCHEMBL22686819 0.81 TP53 (0.46) PTK2ADORA3RAB9AWNT3ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 US disclosed
WO-2016086200-A9 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH, INC. (US) 2016-06-23 WO disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 US disclosed
WO-2012084704-A1 INDAZOLYL TRIAZOLE DERIVATIVES AS IRAK INHIBITORS MERCK SERONO S.A. (CH) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 PTK2 987/4885ADORA3 3550/4885RAB9A 3048/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 PTK2 987/4885ADORA3 3550/4885RAB9A 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.